How much of Cognizant's Q3 2024 revenue growth was organic?

Total reported growth was 3.0% (2.7% constant currency), but recently completed acquisitions, including Belcan and Thirdera, contributed about 200 basis points. Organic growth was therefore roughly 0.7% to 0.8%, though management stated that organic growth was positive both sequentially and year-over-year.

Why did Adjusted Operating Margin decline year-over-year even as GAAP margin improved?

Adjusted Operating Margin fell 20 bps Y/Y to 15.3% (from 15.5%), while GAAP operating margin rose 60 bps to 14.6%. The difference reflects the exclusion of NextGen restructuring charges, which were $33M in Q3 2024 versus $72M in Q3 2023. Adjusted margin is the more comparable underlying measure, and the company's full-year 2024 Adjusted Operating Margin guidance of about 15.1% is flat year-over-year.

What does the weak bookings trend imply for future revenue?

Trailing-twelve-month bookings declined 2% to $26.2B, and Q3 bookings were flat Y/Y. A book-to-bill of about 1.3x still suggests bookings exceed revenue, but the slowing trend is a key watch item. Management is pointing to 19 large deals signed year-to-date and expects stronger Q4 organic growth, which investors should verify in future results.

How did the Belcan acquisition affect Cognizant's balance sheet and liquidity?

Belcan cost about $1.3B in cash and stock. Net cash fell to $809M from $1,996M at year-end 2023, and long-term debt rose to $1,183M from $606M after a $600M revolver draw. Goodwill increased to $7.1B from $6.1B. Free cash flow of $791M in Q3 and continued dividends indicate the company can service its obligations, but leverage and capital allocation flexibility are reduced.

What is the outlook for full-year 2024 and what risks remain?

Guidance calls for FY2024 revenue of $19.7–$19.8B, or 1.4%–1.9% constant-currency growth, including about 200 bps of inorganic contribution. Adjusted Diluted EPS is expected at $4.63–$4.67, and NextGen charges are expected to total about $105M for the year. Key risks cited include the pace of client spending, AI-driven productivity shifts, talent costs, immigration and tax regulation, and integration of Belcan.

CTSH 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Cognizant (CTSH) reported third-quarter 2024 results that landed at the high end of its guidance, with revenue of $5.04 billion^a, up 3.0% year-over-year (2.7% in constant currency).

GAAP operating margin was 14.6% and Adjusted Operating Margin was 15.3%, which was down 20 basis points year-over-year but up 10 basis points sequentially. Adjusted Diluted EPS rose to $1.25^b from $1.16, a gain of about 8%, and GAAP diluted EPS was $1.17 versus $1.04. Roughly 200 basis points of the revenue growth came from recently completed acquisitions, principally Belcan and Thirdera, so organic growth was modest.

Bookings were flat year-over-year in the quarter, and trailing-twelve-month bookings declined 2% to $26.2 billion^c, a book-to-bill of about 1.3x. Segment performance was uneven. Health Sciences grew 7.8% and Financial Services returned to growth at 0.7%, while Communications, Media and Technology declined 3.7%.

Free cash flow was $791 million^d in the quarter, and the company repurchased $228 million of stock and declared a $0.30 quarterly dividend. Net cash fell sharply to $809 million from $1,996 million at year-end 2023, reflecting roughly $1.3 billion in cash and stock consideration for Belcan and higher long-term debt of $1,183 million. Full-year 2024 guidance was narrowed to 1.4% to 1.9% constant-currency revenue growth, unchanged at the midpoint, with Adjusted Operating Margin of about 15.1% (flat year-over-year) and Adjusted Diluted EPS of $4.63 to $4.67.

Management expects fourth-quarter organic growth to exceed the prior-year period and points to large-deal momentum, with 19 deals over $100 million signed year-to-date, as a foundation for 2025. Investors will likely focus on whether that organic acceleration materializes given the weak bookings trend and the balance-sheet impact of the acquisition.

02—Key points

Key Highlights

Q3 2024 revenue of $5.04B grew 3.0% Y/Y (2.7% constant currency) at the high end of guidance, but roughly 200 bps of the growth came from acquisitions, mainly Belcan and Thirdera.
Adjusted Diluted EPS rose to $1.25 from $1.16 (about +8%), while Adjusted Operating Margin of 15.3% declined 20 bps Y/Y; GAAP operating margin was 14.6%, up 60 bps Y/Y.
Bookings were flat Y/Y in Q3; trailing-twelve-month bookings fell 2% to $26.2B (book-to-bill ~1.3x). Six deals of $100M+ were signed in the quarter, bringing the year-to-date count to 19.
Segment mix: Health Sciences +7.8% and Financial Services +0.7% (return to growth), while Communications, Media & Technology declined 3.7%.
Net cash dropped to $809M from $1,996M at year-end 2023, as long-term debt rose to $1,183M from $606M and about $1.3B in cash and stock funded Belcan; Q3 free cash flow was $791M.
FY2024 guidance narrowed to 1.4%–1.9% constant-currency growth (midpoint unchanged), Adjusted Operating Margin ~15.1%, and Adjusted Diluted EPS $4.63–$4.67; Q4 revenue expected at $5.0–$5.1B (+5.1% to +7.1% Y/Y).
Capital returns continued: $228M of buybacks in Q3 (3.1M shares), $1.4B remaining authorization, and a $0.30 quarterly dividend declared for November 2024.

03—Questions

Frequently Asked Questions

How much of Cognizant's Q3 2024 revenue growth was organic?
Total reported growth was 3.0% (2.7% constant currency), but recently completed acquisitions, including Belcan and Thirdera, contributed about 200 basis points. Organic growth was therefore roughly 0.7% to 0.8%, though management stated that organic growth was positive both sequentially and year-over-year.
Why did Adjusted Operating Margin decline year-over-year even as GAAP margin improved?
Adjusted Operating Margin fell 20 bps Y/Y to 15.3% (from 15.5%), while GAAP operating margin rose 60 bps to 14.6%. The difference reflects the exclusion of NextGen restructuring charges, which were $33M in Q3 2024 versus $72M in Q3 2023. Adjusted margin is the more comparable underlying measure, and the company's full-year 2024 Adjusted Operating Margin guidance of about 15.1% is flat year-over-year.
What does the weak bookings trend imply for future revenue?
Trailing-twelve-month bookings declined 2% to $26.2B, and Q3 bookings were flat Y/Y. A book-to-bill of about 1.3x still suggests bookings exceed revenue, but the slowing trend is a key watch item. Management is pointing to 19 large deals signed year-to-date and expects stronger Q4 organic growth, which investors should verify in future results.
How did the Belcan acquisition affect Cognizant's balance sheet and liquidity?
Belcan cost about $1.3B in cash and stock. Net cash fell to $809M from $1,996M at year-end 2023, and long-term debt rose to $1,183M from $606M after a $600M revolver draw. Goodwill increased to $7.1B from $6.1B. Free cash flow of $791M in Q3 and continued dividends indicate the company can service its obligations, but leverage and capital allocation flexibility are reduced.
What is the outlook for full-year 2024 and what risks remain?
Guidance calls for FY2024 revenue of $19.7–$19.8B, or 1.4%–1.9% constant-currency growth, including about 200 bps of inorganic contribution. Adjusted Diluted EPS is expected at $4.63–$4.67, and NextGen charges are expected to total about $105M for the year. Key risks cited include the pace of client spending, AI-driven productivity shifts, talent costs, immigration and tax regulation, and integration of Belcan.

04—Continue

← View all 8-K filings